{
    "relation": [
        [
            "",
            "Pioglitazone",
            "Pioglitazone + Exercise Training"
        ],
        [
            "Description",
            "Pioglitazone (Actos; 30mg/day) for 16 weeks.",
            "Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer."
        ]
    ],
    "pageTitle": "Exercise and Pioglitazone for HIV-Metabolic Syndromes - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00639457?sect=X40156&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042987866.61/warc/CC-MAIN-20150728002307-00301-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 872283255,
    "recordOffset": 872269668,
    "tableOrientation": "VERTICAL",
    "textBeforeTable": "Reporting Groups Exclusion: AIDS diagnosis, non-compliant with anti-HIV medications, unstable CD4+ T-cell count or plasma HIV viremia, illegal drug abuse. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details HIV-infected men and women (18 \u2013 60 yr old) were recruited from the AIDS Clinical Trials Unit, the Infectious Diseases Clinic, and the Volunteers for Health Program at Washington University School of Medicine, St. Louis MO between Jan 2005-Dec 2010. Participants were randomly assigned (1:1) to 4 mo of pioglitazone with or without exercise training. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Pioglitazone Behavioral: Exercise training Interventions: HIV Infections Type 2 Diabetes",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Pioglitazone \u00a0 \u00a0 Pioglitazone + Exercise Training \u00a0 STARTED \u00a0 \u00a0 22 \u00a0 \u00a0 22 \u00a0 COMPLETED \u00a0 \u00a0 20 \u00a0 \u00a0 19 \u00a0 NOT COMPLETED \u00a0 \u00a0 2 \u00a0 \u00a0 3 \u00a0 Withdrawal by Subject \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 3 \u00a0 \u00a0 Baseline Characteristics \u00a0 Hide Baseline Characteristics Population Description Explanation of how the number of",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}